leisure time -WSS

leisure time

author：leisure time 2025-09-30 16:26:00 - browse：9646

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： STAT Boddities: What happens to the brain when we get scared?

knowledge

WSS

Long Covid research funding gets a major boost from NIH

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Long Covid research funding gets a major boost from NIH

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Being 'nonadherent' patient made me a more empathetic doctor

Websites selling Wegovy, Zepbound ingredients targeted by FDA

entertainment

leisure time

knowledge

Apple is now the first public company to be valued at $3 trillion

Hubble vs. James Webb telescope images: See the difference

Novavax promises a turnaround & Lilly roils the obesity market

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

In age of alternative facts, a scholarly course on calling out crap

Congress might make insulin pumps more accessible to the blind

Apple is now the first public company to be valued at $3 trillion

UpToDate has a racism problem: Dr. Stanley Goldfarb

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Dexcom's push to bring CGM to type 2 diabetes patients

leisure time

Canadians with cystic fibrosis outlive Americans by a decade

Ebola vaccine can save some who are already sick, per new study

Skip the lead apron during X

Why Eli Lilly’s earnings didn’t quite live up to the hype

Tome Biosciences co

Congress considering partial increase for doctor pay in Medicare

hotspot

knowledge

entertainment

hotspot